Onco Actu du 8 novembre 2016

	2.9 Etiologie - Tabac
Smoking causes hundreds of genetic mutations [NHS Choices] As the researchers acknowledge, they can't tell from this study the exact biological mechanisms that may be causing the mutations in smokers and non-smokers, or know whether other smoking-related behaviours, such as alcohol consumption, may have an influence.
	3.1.1 Tabac - e-cigs
Kids who use flavored e-cigs more likely to want to try cigarettes [Reuters] The researchers used the National Youth Tobacco Survey, a cross-sectional survey of kids in grades six through 12 in all 50 states. In 2014, about 22,000 students completed the survey, which included questions about using e-cigarettes in the past 30 days.
British American Tobacco to test tobacco e-cigarette in Japan [Reuters] BAT has invested more than $1 billion over the past five years in the development, scale up and launch of cigarette alternatives.
	4.9 Dép., diag. & prono. - Sein
One in six women diagnosed with breast cancer have a symptom other than a lump [Cancer Research UK] Women presenting with breast ulceration, nipple abnormalities, breast infection or inflammation, swollen arm or armpit, and pain in the armpit were more likely to wait longer than three months to seek help.
Warning over non-lump breast cancers [BBC News] The researchers examined the symptoms of 2,300 women who had recently been diagnosed with breast cancer. They found that women with non-lump symptoms were more likely to put off visiting their doctor.
Lack of NHS radiologists 'could cause delays to breast cancer diagnoses' [The Guardian] There are fears that the NHS’s breast cancer screening programme will not be able to cope with the growing numbers of women who will require mammograms in coming years when the age of eligibility is extended from 50-70 to 43-73.
	5. Traitements
Personalised Cancer Vaccines [ESMO] When everything old is new again.
Gold nanoparticles help deliver lethal one-two punch to cancer [Cancer Research UK] By engineering the gold nanoparticles and adding the radioactive tracer, the researchers were able to prove that their drug was reaching the desired target in skin cancer cells grown in the lab and was shutting telomerase down, halting cancer’s growth.
Magic Johnson's HIV Story Offers Hope For Cancer Patients [Forbes] Could it be that we're in a similar position for metastatic cancer in 2016, as for HIV 25 years ago?
	5.12 Immunothérapies
New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting [Merck] First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study.
	5.12.3 Immunothérapies-combinaisons
Roche flags early success for Tecentriq combos, hustles into PhIIIs [EndPoints] Combining Tecentriq with its MEK inhibitor Cotellic along with the BRAF inhibitor Zelboraf delivered an 83% overall response rate in their Phase Ib, with 3 of 24 — out of 29 total previously untreated patients with BRAF mutation-positive melanoma — seeing complete responses.
	5.2 Pharma
Novel system to get dying patients an experimental cancer drug raises hopes — and thorny questions [STAT] Most companies don’t know how to handle such requests. Often, it’s the richest patients, or the best connected, or those who run the most compelling social media campaigns who end up getting the drug. Everyone else is out of luck. Janssen decided on a different approach.
	5.2.1 Pharma - Partenariats
Cancer Research UK enters new oncology partnership [Pharmafile] The partnership plans to take TYG’s antigen-specific, active checkpoint control cancer vaccine TYG100 and use it as a base to develop the new preventative treatment. TYG100 prevents tumour growth by targeting the hormones responsible and triggers production of antibodies.
	5.3 Traitements - FDA, EMA, NICE...
Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs [Forbes] If one didn’t know any better, based on Cruz’s comments, one would think that the FDA is lagging the rest of the world with respect both to the approval of new drugs and the time the Agency is taking to approve new breakthroughs. Actually, that isn’t the case.
	5.4 Traitements - Economie
CMS official says drug costs are ‘unsustainable’ and there are ‘too many’ bad actors [STAT] “Drug costs have become the health policy issue Americans are most anxious to see us act on, and we have a responsibility to them to explore all the options available us to make their medications more affordable.”
Roche says flexible pricing ready for cancer, not MS drugs [Reuters] Roche has introduced flexible pricing for cancer drugs in about a dozen European countries, including Italy, Belgium, Hungary, Switzerland and Austria. For instance, it already prices drugs like Avastin differently in some markets depending on the cancer being targeted.
	5.8.1 ASH - Communiqués
Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting [Cellectis] Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART).
	6. Lutte contre les cancers
New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients [Boehringer Ingelheim] Data showed that 60% of physicians prioritised factors related to maintaining quality of life, achieving disease stability or tumour response, whilst less than half of the physicians prioritised extending overall survival as a primary therapy goal for patients.
	6.1 Observation
Childhood cancer survivors have lasting health problems even with newer treatments [Reuters] Up to one in four childhood cancer survivors report health problems in their 20s and 30s, researchers report in the Annals of Internal Medicine.
	6.10.1 Politiques (USA)
Drug pricing fight in California turns nasty with ads tarring pharma execs as criminals [STAT] The “Wanted” ads, which will run on TMZ, Facebook, Politico and other online sites, target Allergan’s Brent Saunders, Johnson & Johnson’s Alex Gorsky, Merck’s Kenneth Frazier, Pfizer’s Ian Read, AbbVie’s Richard Gonzalez, and Amgen’s Robert Bradway.
	6.11 Patients
Positive Psychology and Health [Science-Based Medicine] To imply that one can will away or believe oneself out of the pain and long-term effects of a disease is a grave insult to many of us who are doing our absolute best to cope with devastating conditions.
	6.3 Associations/Fondations
U.K. investors team up to create $1.2B cancer-focused fund [FierceBiotech] BACIT, an acronym for Battle Against Cancer Investment Trust, has a completely different approach to investing and funding research. The company invests in other funds to generate returns for its backers while siphoning off money for charitable donations to the Institute of Cancer Research and other nonprofits.
Cancer Research UK joins forces with Wellcome Trust, Syncona and BACIT to create life sciences champion [Cancer Research UK] Cancer Research UK, the world’s largest independent supporter of cancer research, is delighted to announce that it is aligning with the Wellcome Trust, Syncona and BACIT to create an up to £1 billion company to invest in life sciences, with a significant allocation to oncology, subject to approval from BACIT shareholders.
	6.4 Médico-éco
‘Massive inequities’ exist among countries for essential medicines [STAT] The report arrives at a time of increasing concern over the inequities on pharmaceutical spending, but also rising anxiety across the globe over the cost of medicines.